Premier Healthcare Germany

20/02/2023

Cancer treatment from Biontech is to become part of everyday life by 2030

Clinical trials in the UK are set to begin soon to bring Biontech's cancer drug to market.

To bring the cancer vaccines to market, the company has agreed clinical trials in the UK to begin later this year. At the moment, the vaccine candidates, cancer types and locations for it would be selected. But the technology is already well advanced, says Şahin. “In 2014, it took us three to six months to produce an individualized cancer vaccine; we are currently four to six weeks. Our goal is to come in well under four weeks.”

https://www.faz.net/aktuell/wirtschaft/krebsbehandlung-von-biontech-soll-bis-2030-alltag-werden-18690208.html

Klinische Studien in Großbritannien sollen bald anlaufen, um das Krebsmittel von Biontech zur Marktreife zu bringen. Die Chefs des Mainzer Unternehmens zeigen sich optimistisch hinsichtlich der Wirksamkeit.

14/02/2023

Leukemia: Blood cancer is the most common cancer in children

In Germany, hundreds of children and young people are diagnosed with blood cancer every year. In some cases, an uncomplicated stem cell donation can save the lives of those affected.

"In the past few decades, there have been great advances in the treatment of most malignant diseases that occur in children and adolescents,"

PHG has assisted many children with Leukemia treatment, contact us for more information!

https://www.spiegel.de/gesundheit/leukaemie-blutkrebs-ist-haeufigste-krebsart-bei-kindern-a-23db44bc-3c83-477b-af53-8564bfa1ba79 =rss

In Deutschland bekommen jedes Jahr Hunderte Kinder und Jugendliche die Diagnose Blutkrebs. In manchen Fällen kann eine unkomplizierte Stammzellspende das Leben der Betroffenen retten.

14/11/2022

14 November is World diabetes day!

World Diabetes Day is taking place for the 31st time this year: it was introduced in 1991 by the International Diabetes Federation (IDF) and the World Health Organization (WHO) as a global day of action to draw attention to the increasing spread of diabetes mellitus.

Access to Diabetes Care: If Not Now, When?

11/11/2022

CRISPR cancer trial success paves the way for personalized treatments

A small clinical trial has shown that researchers can use CRISPR gene editing to alter immune cells so that they will recognize mutated proteins specific to a person’s tumours. Those cells can then be safely set loose in the body to find and destroy their target.
It is the first attempt to combine two hot areas in cancer research: gene editing to create personalized treatments, and engineering immune cells called T cells so as to better target tumours. The approach was tested in 16 people with solid tumours, including in the breast and colon.

CRISPR cancer trial success paves the way for personalized treatments (nature.com)

31/10/2022

Lung cancer: How tumor cells flee from the immune cells

cancer is characterized in particular by the property that it can influence the body's own defense system. But how exactly do cancer cells escape the defense mechanisms of the immune system? British researchers have developed a computer-aided method to find out more about it. This also helps in the development of new targeted active ingredients.

Lung cancer: How tumor cells flee from immune cells • DGP (deutschesgesundheitsportal.de)

24/10/2022

Hope and challenge of CAR-T

Genetically modified CAR-T cells achieve high response rates and partially permanent remissions in patients with advanced hemato-oncological diseases. Cell therapy, classified as gene therapy by the European Medicines Agency (EMA), enables a specific immunological tumour response. The patient's immune cells (T-lymphocytes) are genetically modified in the laboratory in such a way that they can detect and destroy the cancer cells in the patient's body by means of an artificial (chimeric) antigen-specific receptor (CAR). To date, six CAR-T cell therapies have received EU approval.

Hope and challenge | PZ – Pharmazeutische Zeitung (pharmazeutische-zeitung.de)

-T

26/09/2022

MS therapy with cladribine over 8 years

Cladribine is approved for the treatment of highly active relapsing multiple sclerosis (MS) to halt disease progression. The disease progression of 27 patients from three clinical studies has now been analyzed over 8 years after the end of the study and showed a reduced risk of disease progression and transition to progressive courses with cladribine

https://www.deutschesgesundheitsportal.de/2022/09/23/nachbeobachtung-der-ms-therapie-mit-cladribin-ueber-8-jahre/

Cladribin ist zur Behandlung hoch-aktiver rückfälliger Multipler Sklerose (MS) zugelassen, um den Krankheitsfortschritt aufzuhalten. Der Krankheitsverlauf von 27 Patienten aus drei klinischen Studien wurde nun über 8 Jahre nach Studienende analysiert und zeigte bei Cladribin versus Placebo ein re...

19/09/2022

Pleural mesothelioma: Immunotherapy as a first-line standard superior even after four years

Malignant pleural mesothelioma is one of the most resistant malignant tumors. Very few diseases are operable, and systemic therapy has only developed positively in recent years with the introduction of immunotherapy.

Very few mesothelioma diseases are operable, and the standard first-line therapy in this situation is now the combination of the PD-1 inhibitor nivolumab and the CTLA-4 inhibitor ipilimumab.

https://www.aerzteblatt.de/nachrichten/137439/Pleuramesotheliom-Immuntherapie-als-Erstlinienstandard-auch-nach-vier-Jahren-ueberlegen

15/09/2022

Atezolizumab and pembrolizumab in triple-negative breast cancer: a meta-analysis

A meta-analysis examined new drugs for the treatment of triple-negative breast cancer. This difficult-to-treat type of breast cancer is often associated with a poor prognosis . But the drugs atezolizumab and pembrolizumab could represent new treatment options. The analysis showed higher effectiveness of the drugs in combination with chemotherapy than treatment with chemotherapy alone.

https://deutschesgesundheitsportal.de/2022/09/14/immuncheckpoint-inhibitoren-atezolizumab-und-pembrolizumab-triple-negativ-brustkrebs/

13/09/2022

Basal cell carcinoma diagnosis improved with new imaging technique

Basal cell carcinoma can be diagnosed more accurately than with either clinical or dermoscopic examination using a novel imaging technique according to data presented at the 31st European Academy of Dermatology and Venereology (EADV) Congress by researchers from the Department of Dermatology at the Hôpital Erasme, Université Libre de Bruxelles, Brussels.

Basal cell carcinoma diagnosis improved with novel imaging technique - Hospital Healthcare Europe

09/09/2022

Breast cancer: Mendelian randomization confirms physical inactivity as a risk factor

Women who are physically active and spend little time sedentary are less likely to develop breast cancer.

In recent years, the results of epidemiological studies have been supported by so-called Mendelian randomization. These studies assume certain gene variants (SNP) that were associated with reduced physical activity in genome-wide association studies (GWAS). Physical movement was often measured objectively using pedometers and other accelerators, whereas previous studies often relied on information from questionnaires, which are not necessarily correct.

https://www.aerzteblatt.de/nachrichten/137203/Brustkrebs-Mendelsche-Randomisierung-bestaetigt-Bewegungsmangel-als-Risikofaktor?

Melbourne – Frauen, die körperlich aktiv sind und wenig Zeit im Sitzen verbringen, erkranken seltener an Brustkrebs. Dies zeigen die Ergebnisse einer...

05/09/2022

ROBO3 receptor mediates therapy resistance and metastasis

The diagnosis of pancreatic cancer is still associated with a poor clinical prognosis. At the time of diagnosis, most patients are already in an advanced stage and curative therapy by surgical removal of the tumor is no longer possible. Chemotherapy is the treatment of choice for metastatic pancreatic cancer. However, the majority of patients are resistant to the currently available chemotherapy regimens. The treatment is often not effective enough and not long-term. Less than nine percent of patients survive the following five years after diagnosis.

Researchers examined sequencing data from samples from pancreatic cancer patients. They found that axon conduction signaling pathways were exclusively enriched in basal-like tumors. In particular, the ROBO3 expression was significantly higher in the different data sets of patients in the basal-like subtype.

https://www.krebs-nachrichten.de/forschung-details/robo3-rezeptor-vermittelt-therapieresistenz-und-metastasierung.html

Die Diagnose „Bauchspeicheldrüsenkrebs“ ist immer noch mit einer schlechten klinischen Prognose verbunden. Zum Zeitpunkt der Diagnose weisen die meisten Patient*innen bereits ein fortgeschrittenes Stadium auf und eine kurative Therapie durch chirurgische Entfernung des Tumors ist nicht mehr mö...